Wechselwirkungen · Urorec
Urorec 4 mg hard capsules Urorec 8 mg hard capsules · Abschnitt 4.5 · PDF-Seite 4
HOS-211761 · Präparat HOS-154747
CYP3A4 inhibitors In an interaction study, a 3.7-fold increase in maximum silodosin plasma concentrations and a 3.1-fold increase in silodosin exposure (i.e. AUC) were observed with concurrent administration of a potent CYP3A4 inhibitor (ketoconazole 400 mg). Concomitant use with potent CYP3A4 inhibitors (such as ketoconazole, itraconazole, ritonavir or cyclosporine) is not recommended. When silodosin was co-administered with a CYP3A4 inhibitor of moderate potency such as diltiazem, an increase in silodosin AUC of approximately 30% was observed, but Cmax and half-life were not affected. This change is clinically not relevant and no dose adjustment is required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) ketoconazole (HOS-084513) itraconazole (HOS-084516) ritonavir (HOS-084521) cyclosporine (HOS-084512)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-07T08:40:00Z · SHA-256 e9c36de8215b17cc4a647a7ae8e9d3c56d37fc42f394cbf02ce5f9e8f8bf6c2d · Passage d853d3ec20e26ad7df66ea2bdc61daf5cdd84dea2545ab39b43437516f0a2734 · Zeichen 637–1305 im Abschnitt